Skip to Content
Merck
All Photos(1)

Key Documents

SML2840

Sigma-Aldrich

AZD2066

≥98% (HPLC)

Synonym(s):

4-[5-[(1R)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine, AZD 2066

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C19H16ClN5O2
CAS Number:
Molecular Weight:
381.82
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

InChI

1S/C19H16ClN5O2/c1-12(16-11-17(27-24-16)14-4-3-5-15(20)10-14)26-19-23-22-18(25(19)2)13-6-8-21-9-7-13/h3-12H,1-2H3/t12-/m1/s1

InChI key

SXWHYTICXCLKDG-GFCCVEGCSA-N

Biochem/physiol Actions

AZD2066 is an orally bioavailable, brain penetrant, selective and potent negative allosteric modulator of the metabotropic glutamate receptor subtype 5 (mGlu5). AZD2066 exhibited satisfactory efficacy in patients suffering from neuropathic pain with mechanical hypersensitivity.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Matts Kågedal et al.
NeuroImage, 82, 160-169 (2013-05-15)
AZD2066 is a new chemical entity pharmacologically characterized as a selective, negative allosteric modulator of the metabotropic glutamate receptor subtype 5 (mGluR5). Antagonism of mGluR5 has been implicated in relation to various diseases such as anxiety, depression, and pain disorders.
Brittany A Jaso et al.
Current neuropharmacology, 15(1), 57-70 (2016-03-22)
Current pharmacotherapies for major depressive disorder (MDD) have a distinct lag of onset that can prolong distress and impairment for patients, and realworld effectiveness trials further suggest that antidepressant efficacy is limited in many patients. All currently approved antidepressant medications
Michael D B Swedberg et al.
The Journal of pharmacology and experimental therapeutics, 350(2), 212-222 (2014-05-31)
The metabotropic glutamate receptor 5 (mGluR5) antagonists fenobam, MPEP (2-methyl-6-(phenylethynyl)pyridine), and MTEP (3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine) were previously shown to not cause N-methyl-D-aspartate antagonist-like psychoactive effects in phencyclidine (PCP) drug discrimination studies, but to cause MTEP-like discrimination in rats, suggesting that the psychoactive

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service